Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

ipatasertib 1entinostat 1Specimen Handling 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
50 enrolled 12 charts
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡